

Special Issue

Immune Response to the Vaccines against Foot-and-Mouth Disease and Other Similar Animal Diseases

Message from the Guest Editors

At present, vaccination remains the most powerful tool to contain Foot-and-mouth disease (FMD) and other similar diseases. Because of the high mutation rate of FMDV and other similar viruses, vaccines need to be continuously improved and tailored to the specific strains causing an outbreak. Numerous issues may compromise the efficacy of currently used vaccines, such as the dangerous large-scale amplification of the virus to be inactivated for vaccine production, the limited duration of immunity induced by the vaccine administration, the possibility of the development of carriers even between vaccinated animals and the need for an efficient cold chain. In this Special Issue, all papers that gather knowledge on some of the yet-unanswered questions regarding the immune response of animals to vaccination, the mechanisms able to enhance immunity, the in-field evaluation of newly developed vaccines and the new technologies improved to produce new generations of vaccines are welcome. Studies that clarify the relationship between FMDV and other similar viruses and host immune responses are also welcome.

Guest Editors

Dr. Efrema Alessandro Foglia

Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZSLER), 25124 Brescia, Italy

Dr. Tiziana Trogu

Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZSLER), 25124 Brescia, Italy

Deadline for manuscript submissions

closed (30 November 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/122586

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).